Primary Central Nervous System Neoplasm

subtype

Identifier: CI-CAN-00001432
Entity page: /cancer/primary-central-nervous-system-neoplasm ↗
Edges: 3,925

Neighbours: 15 genes18 drugs10 trials
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Primary Central Nervous System Neoplasm approved for …APPROVED_FORderived15 of 19show all (up to 200)
← approved for	Dordavipronesmall molecule FDA (US) · approved · 2025-08-06 · MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 …	—	approved	Diffuse Midline Glioma	1	Regulatory	openfda	graph →
approved for

Primary Central Nervous System Neoplasm altered in cohorts of …ALTERED_INderived15 of 437show all (up to 200)
← altered in cohorts of	ATRNL1 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MYOF 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SEC23IP 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	BAG3 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CACUL1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EIF3A 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	INPP5F 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MCMBP 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	PRLHR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTA2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CTBP2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CYP26C1 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	DENND10 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	GFRA1 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →

Primary Central Nervous System Neoplasm altered in cohorts of …ALTERED_INderived15 of 437show all (up to 200)

← altered in cohorts of

ATRNL1

456 / 601 cases (76 %) · ssm · TCGA-GBM

—

Glioblastoma

Observed

Primary Central Nervous System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 236show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 387 trials (122 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	387	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 148 trials (26 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	148	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 59 trials (27 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	59	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 51 trials (26 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Lomustinesmall molecule 50 trials (15 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 43 trials (14 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 43 trials (18 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 35 trials (7 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 30 trials (12 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 29 trials (11 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 25 trials (11 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 24 trials (11 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 23 trials (5 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 23 trials (11 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 21 trials (1 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Neoplasm	21	Observed	clinicaltrials	graph →

Primary Central Nervous System Neoplasm studied in …STUDIED_INderived10 of 3,233show all (up to 200)
→ studied in	NCT01445288completed Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors · condition mapped ONTOLOGY_EXACT · 3,233 trials mapped (1,106 active)	—	—	Diffuse Intrinsic Pontine Glioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303467Phase 1 · recruiting A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT07145112Phase 1 · recruiting Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07326566Phase 2 · recruiting Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07346157Phase 1/Phase 2 · recruiting Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Medulloblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07416188Phase 1/Phase 2 · recruiting Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 3,233 trials mapped (1,106 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03702309recruiting Liquid Biopsy Evaluation and Repository Development at Princess Margaret · condition mapped ONTOLOGY_EXACT · 3,233 trials mapped (1,106 active)	—	—	Meningioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03896568Phase 1 · recruiting MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma · condition mapped CURATED_BROADER · 3,233 trials mapped (1,106 active)	—	—	Anaplastic Astrocytoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains